• Neurogenic Drug Improves Depression in Small Trial

By Cynthia Fox, Drug Discovery & Development, June 16, 2014

Science Editor Cynthia Fox issued a report on first-in-class neurogenic NSI-189/major depressive disorder (MDD) Phase I data, presented by Mass Gen/Harvard’s Dr. Marlene Freeman, at ASCP’s annual meeting. She reports that “depressed patients taking two different doses of the drug have now experienced a ‘clinically meaningful’ relief of depressive and cognitive symptoms across all measures in comparison to placebo. This relief continued throughout the follow-up period,” which was for two months following the 28-day dosing. Neuralstem’s President and CEO, Richard Garr, is quoted as saying, “this is a very solid sign pointing to confirming our thesis that what we see in animals—structurally rebuilding the hippocampus—is also happening in humans.”

View Article

• Neuralstem could seek partner for Phase II depression small molecule; to develop stem cell therapy solo – CEO

By Hamish McDougall, BioPharm Insight, April 25, 2014

Neuralstem’s President and CEO discusses neurogenic small molecule lead compound, NSI-189, commercialization strategy with global life sciences business intelligence group, BioPharm Insight. Garr notes a partnership commitment would require the full potential of NSI-189 as a neurogenic agent in all potential indications on a global basis. The company plans to file an IND in late summer or early 3Q14 to commence the NSI-189 Phase II clinical trial in major depressive disorder before year-end, with Dr. Maurizio Fava, professor of Psychiatry, Harvard Medical School, cited as likely to be the principal investigator.

View News Report

• New trial may be step forward for spinal cord injuries

By Miriam Falco, CNN Medical Managing Editor, CNN, April 16, 2014

CNN Medical Managing Editor, Miriam Falco, reports on the promise of NSI-566 for chronic spinal cord injury, approved to commence a Phase I trial at the University of California, San Diego, School of Medicine. July is cited as the potential first treatment date by Neuralstem’s CSO Karl Johe, PhD. In the article, Dr. Johe and President and CEO Richard Garr give insights on the ability of NSI-566 to "actually build new circuitry” and “jump the gap with the new circuitry we've built.”

View Article

• Neuralstem doses ischemic stroke patient with stem cells directly into the brain

By Shannon Ellis, BioWorld Asia, February 5, 2014

“It is a crucial step forward for the company and the field at large, since optimizing cell therapy treatment for CNS indications will require delivering cells to the brain, as well as to the spinal cord.” - Neuralstem's Chairman and CSO, Karl Johe, PhD, quoted in BioWorld's article on the ongoing NSI-566/ischemic stroke trial in Beijing.

View Article

• Stem cell trial seeks longer lives for victims of deadly ALS

By Ben Gruber, Reuters, January 8, 2014

NSI-566/ALS Emory University Site Principal Investigator, Jonathan D. Glass, M.D., and Phase II patient, April Moundzouris, are featured in this video news story by Reuters’ Ben Gruber. Dr. Glass notes that Neuralstem’s cell therapy and the trial investigators are working towards “chang(ing) the slope” of ALS to “become a chronic disease, as opposed to a terminal disease.”

View Video

• Neuralstem’s $19.6M offering takes ALS bid through phase II

By Randy Osborne, BioWorld Today, January 6, 2014

In a front-page feature story, BioWorld Today’s Randy Osborne talks to Neuralstem’s President and CEO, Richard Garr, about the recent financing announcement and how, upon expected closing, it will impact current and upcoming clinical trials, including NSI-566/ALS Phase II, NSI-189/MDD
Phase II filing, and FDA-approved NSI-566/cSCI Phase I. The article also explores the company’s novel approach to cell therapy and the mechanisms of action by NSI-566 for different indications, such as building new circuitry to “bridge the gap” in spinal cord injury.

View Article

• A Closer Look At Neuralstem’s ALS Treatment

By John Farrell, Forbes, November 21, 2013

Science and technology writer John Farrell explores the business and science sides of Neuralstem’s NSI-566, currently in an ongoing Phase II ALS trial. Neuralstem’s President and CEO, Richard Garr, is quoted extensively on the differentiation and commercialization aspects of the proprietary neural stem cell technology, and gives a forward-looking view of both the ALS trial, and additional planned NSI-566 trials, in this “Pharma & Healthcare” business feature.

View Article

• Georgia men undergo risky surgery in battle against ALS

By Beth Galvin, FOX Atlanta, November 20, 2013

FOX Medical Team Reporter Beth Galvin continues her coverage of Neuralstem’s ongoing NSI-566/ALS Phase II trial with a patient perspective piece featuring Ted Harada and John Conley, both treated during Phase I at Emory University Hospital.

View Segment

• Risky surgery provides hope for ALS patients

By Beth Galvin, FOX Atlanta, November 5, 2013, Updated 11/6/13

FOX Medical Team’s Beth Galvin reports on Neuralstem’s first NSI-566/ALS Phase II patient, Kathy Lingle, two months post-treatment of ten injections of a total of two million cells at Emory University Hospital in this sweeping feature segment that includes graphic footage of the surgery that “is almost becoming routine.” Site Principal Investigator Dr. Jonathan Glass and Co-Investigator and Neurosurgeon Dr. Nicholas Boulis share insights on exposing “the riskiest real estate in the body,” the cervical spinal cord, “the most important and the most dangerous” in patients’ quest for a cure that Beth Galvin says, “all comes down to one word: hope.”

View Segment